Zoledronic acid vs Teriparatide
Written by Aaron CuhaReviewed Sep 2026
The short answer
The two ends of osteoporosis treatment. One is a once yearly drip that slows bone loss, and the other is a daily shot that builds bone. Zoledronic acid also has the most interesting unexplained death rate signal in ageing research. After hip fracture, 9.6 percent died on it against 13.3 percent on a dummy drip. A review of 38 osteoporosis drug trials did not confirm that.
- Zoledronic acid people
- 7,176
- Zoledronic acid nulls
- 0
- Teriparatide people
- 1,637
- Teriparatide nulls
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved. Sold as Reclast for thin bones (osteoporosis) in women after menopause and in men, for thin bones caused by steroid drugs, and for Paget disease of bone. Sold as Zometa for high blood calcium caused by cancer, and for cancer that has spread to bone. It is not approved for ageing, longevity or helping people live longer, and no one has asked for that use.
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved (Forteo) for osteoporosis
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
Zoledronic acidZoledronic acid, an intravenous nitrogen-containing bisphosphonate
An approved once-a-year bone drip with an odd, unexplained link to fewer deaths. In a study of people after a broken hip, 9.6 percent died on zoledronic acid against 13.3 percent on a dummy drip. Deaths were a side finding, and nobody has explained them. A review that pooled 38 osteoporosis drug studies then found no drop in deaths.
Column B
TeriparatideTeriparatide (parathyroid hormone 1-34)
An FDA-approved bone-building shot. It is a piece of parathyroid hormone, used for severe bone thinning.
Side by side, on the facts we can check
| What we compare | Zoledronic acid | Teriparatide |
|---|---|---|
| Category | Longevity | Hormone |
| FDA status | FDA-approved. Sold as Reclast for thin bones (osteoporosis) in women after menopause and in men, for thin bones caused by steroid drugs, and for Paget disease of bone. Sold as Zometa for high blood calcium caused by cancer, and for cancer that has spread to bone. It is not approved for ageing, longevity or helping people live longer, and no one has asked for that use. | FDA-approved (Forteo) for osteoporosis |
| Half-life | Plasma clearance is rapid and multiphasic, but the drug binds to bone mineral and is released slowly over years as bone turns over, so no single plasma figure describes its duration of action. This is why it is dosed once a year. | ~1 hour |
| Molecular weight | 272.1 Da for the anhydrous acid. | 4,117.8 Da |
| How it works | Zoledronic acid sticks tightly to bone. Bone-clearing cells, called osteoclasts, take it up. Inside them it blocks an enzyme the cell needs, so the osteoclast stops breaking down bone and dies. That is the proven way it works, and it fully explains the drop in broken bones. It does not explain the drop in deaths. Ideas for effects beyond bone include clearing or quieting zombie cells. Mayo Clinic work supports that idea: the drug killed zombie cells in a dish, and in old mice it cut inflammatory signals in the blood and improved grip strength. Other ideas are effects on young bone-clearing cells that carry zombie markers, and broad effects on immune cells. None of these has been shown to explain the survival gap in people. | A short daily hit on the parathyroid hormone receptor switches on bone-building cells. That raises bone density and strength. |
| Studies in people | 4 | 2 |
| Evidence | Strong: 4 completed trials, 7,176 people given it | Moderate: 1 completed trial, 1,637 people given it |
| Legal status, US | FDA-approved, prescription only | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Zoledronic acid and Teriparatide?
Zoledronic acid: An approved once-a-year bone drip with an odd, unexplained link to fewer deaths. In a study of people after a broken hip, 9.6 percent died on zoledronic acid against 13.3 percent on a dummy drip. Deaths were a side finding, and nobody has explained them. A review that pooled 38 osteoporosis drug studies then found no drop in deaths. Teriparatide: An FDA-approved bone-building shot. It is a piece of parathyroid hormone, used for severe bone thinning.
Which has stronger research evidence, Zoledronic acid or Teriparatide?
Each compound gets a band worked out from facts we counted, with the math shown. Zoledronic acid is Strong (4 completed trials, 7,176 people given it). Teriparatide is Moderate (1 completed trial, 1,637 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Zoledronic acid and Teriparatide FDA-approved?
Zoledronic acid: FDA-approved. Sold as Reclast for thin bones (osteoporosis) in women after menopause and in men, for thin bones caused by steroid drugs, and for Paget disease of bone. Sold as Zometa for high blood calcium caused by cancer, and for cancer that has spread to bone. It is not approved for ageing, longevity or helping people live longer, and no one has asked for that use.. Teriparatide: FDA-approved (Forteo) for osteoporosis.
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.